Autor(es)Masrinoul Promsin, Puiprom Orapim, Tanaka Atsushi, Kuwahara Miwa, Chaichana Panjaporn, Ikuta Kazuyoshi, Ramasoota Pongrama, Okabayashi Tamaki

ResumoChikungunya virus (CHIKV) causes an acute clinical illness characterized by sudden high fever, intense joint pain, - skin rash. Recent outbreaks of chikungunya disease in Africa - Asia are a major public health concern; however, there is currently no effective licensed vaccine or specific treatment. This study reported the development of a mouse monoclonal antibody (MAb), CK47, which recognizes domain III within the viral envelope 1 protein - inhibited the viral release process, thereby preventing the production of progeny virus. The MAb had no effect on virus entry - replication processes. Thus, CK47 may be a useful tool for studying the mechanisms underlying CHIKV release - may show potential as a therapeutic agent.

Palavras-ChaveChikungunya virus; Monoclonal antibody; Post-entry inhibitory step

ImprentaVirology, v. 464-465, p. 111-117, 2014

DescritoresChikungunya virus - Pathogenesis ; Chikungunya virus - Proteins ; Chikungunya virus - Antibodies ; Chikungunya virus - Infectious diseases ; Chikungunya virus - Viral infections ; Chikungunya Virus - Virus ; Chikungunya virus - Vaccine ; Chikungunya virus - Chikungunya fever ; Chikungunya virus - Immunology ; Chikungunya virus - Public health

Data de Publicação:2014